Head and neck cancer trials in South Korea
30 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleStudy of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Where
- Busan, Cheongju-si, Gyeonggi-do, Hwasun, Incheon, Seongnam-si, Seoul, Suwon
- Age
- 18 years and over
- People
- 340 worldwide
- Run by
- Inhibrx Biosciences, Inc
See details and how to joinNCT04198766 - Phase 1Taking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- Seoul
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - Phase 3Taking peopleJNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
- Where
- Seoul, Suwon
- Age
- 60 years and over
- People
- 500 worldwide
- Run by
- Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT04892173 · EU 2024-520386-31-00 - Phase 1/2Taking peopleA Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- Where
- Seoul
- Age
- 18 years and over
- People
- 287 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06385080 · EU 2023-508418-40-00 - Phase 3Taking peopleA Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- Where
- Seoul
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07276399 · EU 2025-521917-24-00 - Phase 2/3Taking peopleFORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Where
- Busan, Goyang-si, Hwasun, Seongnam, Seoul
- Age
- 18 years and over
- People
- 650 worldwide
- Run by
- Bicara Therapeutics
See details and how to joinNCT06788990 · EU 2024-519654-37-00 - Phase 2/3Taking peopleOrdastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
- Where
- Daegu, Seoul, Yangsan
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Inhibrx Biosciences, Inc
See details and how to joinNCT06295731 - Phase 1/2Taking peopleA Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
- Where
- Goyang-si, Seoul
- Age
- 18 years and over
- People
- 235 worldwide
- Run by
- Alentis Therapeutics AG
See details and how to joinNCT06747585 · EU 2024-515459-39-00 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Daegu, Gyeonggi-do, Seongnam, Seoul
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 1Taking peopleStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Where
- Busan, Cheongju-si, Jinju, Seoul
- Age
- 18 years and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00 - Phase 1Taking peopleA Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
- Where
- Seoul
- Age
- 18 years and over
- People
- 110 worldwide
- Run by
- EpiBiologics
See details and how to joinNCT07462377 - Phase 1/2Taking peopleA Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Where
- Seoul
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07115043 - Phase 3Taking peopleA Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
- Where
- Busan, Jeonju, Seongnam, Seongnam-si, Seoul, Suwon, Yangsan
- Age
- 18 years and over
- People
- 260 worldwide
- Run by
- Corbus Pharmaceuticals Inc.
See details and how to joinNCT07768189 · EU 2026-527123-94-00 - Phase 1/2Taking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Seoul
- Age
- 12 years and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - Phase 3Taking peopleA Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
- Where
- Goyang-si, Gyeonggi-do, Incheon, Seoul, Suwon
- Age
- 18 years to 130 years
- People
- 1,145 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06129864 - Phase 2Taking peopleStudy of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
- Where
- Incheon, Namdong-gu, Seoul
- Age
- 18 years to 64 years
- People
- 257 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06535607 · EU 2025-523947-36-00 - Phase 1/2Taking peopleA Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.
- Where
- Seoul
- Age
- 19 years and over
- People
- 37
- Run by
- Cellid Co., Ltd.
See details and how to joinNCT06797986 - Phase 1Taking peopleA Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Where
- Cheongju-si, Goyang-si, Seoul
- Age
- 18 years and over
- People
- 1,006 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT04389632 · EU 2023-508469-34-00 - Phase 1Taking peopleStudy to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Where
- Goyang-si, Seongnam, Seoul
- Age
- 18 years and over
- People
- 694 worldwide
- Run by
- AbbVie
See details and how to joinNCT05005403 - Phase 1/2Taking peopleClinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
- Where
- Seoul
- Age
- 18 years and over
- People
- 80
- Run by
- Yuhan Corporation
See details and how to joinNCT06975410 - Phase 1Taking peopleStudy With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- Where
- Seoul
- Age
- 18 years and over
- People
- 248 worldwide
- Run by
- Calico Life Sciences LLC
See details and how to joinNCT04777994 · EU 2023-507568-38-00 - Phase 1/2Taking peopleA Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
- Where
- Cheongju-si, Seongnam-si, Seoul, Suwon
- Age
- 18 years and over
- People
- 398 worldwide
- Run by
- Hummingbird Bioscience
See details and how to joinNCT05910827 - Phase 3Taking peopleA Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- Where
- Busan, Pusan, Seoul, Suwon Gyeonggi-do
- Age
- 18 years and over
- People
- 864 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06256588 · EU 2023-508613-17-00 - Phase 3Taking peopleA Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
- Where
- Daegu, Seoul, Suwon
- Age
- 18 years and over
- People
- 410 worldwide
- Run by
- AVEO Pharmaceuticals, Inc.
See details and how to joinNCT06064877 · EU 2023-505606-42-00 - Phase 1Taking peopleStudy to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
- Where
- Goyang-si, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 51
- Run by
- Oscotec Inc.
See details and how to joinNCT07358806